Wave Life Sciences LTD 8-K filings

Wave Life Sciences, Inc. has successfully completed its redomiciliation to Delaware, with Wave-Delaware becoming the ultimate parent company and its common stock set to trade on Nasdaq under the symbol WVE.

Wave Life Sciences announced Q2 2026 financial results, highlighting progress in its obesity, AATD, and PNPLA3 liver disease programs, with a strong cash position extending runway into Q3 2028.

Wave Life Sciences Ltd. shareholders have voted to approve a scheme of arrangement to redomicile the company from Singapore.

Wave Life Sciences announced positive data from its RestorAATion-2 trial for WVE-006, showing potential to treat both lung and liver manifestations of AATD with a convenient, safe, and durable therapy.

Wave Life Sciences reported Q1 2026 financial results, highlighting advancements in its WVE-007 obesity program, WVE-006 AATD treatment, and WVE-008 liver disease program, while maintaining a strong cash position.

Wave Life Sciences has scheduled a Singapore High Court hearing for April 29, 2026, to advance its proposed redomiciliation to the United States.

Wave Life Sciences Ltd. announced a plan to redomicile its parent company from Singapore to the United States, aiming for administrative efficiencies and streamlined operations.

Wave Life Sciences announced positive interim Phase 1 data for WVE-007, demonstrating significant reductions in visceral fat and waist circumference with muscle preservation.

Wave Life Sciences announced its fourth quarter and full year 2025 financial results, highlighting progress in its obesity, AATD, and liver disease programs and extending its cash runway into Q3 2028.

Wave Life Sciences announced it has regained full rights to WVE-006 for Alpha-1 Antitrypsin Deficiency, accelerating regulatory engagement and anticipating key clinical trial data.

Wave Life Sciences highlights strategic priorities for 2026, accelerating WVE-007 for obesity and advancing its RNA editing portfolio, backed by a strong cash position.

Wave Life Sciences Ltd. announced the pricing of an upsized public offering of ordinary shares and pre-funded warrants, expecting to raise approximately $402.5 million to extend its cash runway.

Wave Life Sciences announced positive interim Phase 1 data for WVE-007, an investigational obesity treatment, showing significant fat loss without muscle loss.

Wave Life Sciences provides a corporate update highlighting positive clinical data across its RNA editing, RNAi, splicing, and allele-selective silencing programs, extending cash runway into Q2 2027.

Wave Life Sciences announced positive clinical trial results for its obesity and AATD programs, alongside an extended cash runway into Q2 2027.

Wave Life Sciences announced positive target engagement data for its obesity drug WVE-007, showing significant Activin E reductions in its INLIGHT clinical trial.

Wave Life Sciences announced positive target engagement data from its INLIGHT clinical trial for WVE-007 in obesity and unveiled WVE-008 for liver disease.

Wave Life Sciences Ltd. updated its corporate presentation, highlighting significant progress in its RNA medicines pipeline, including positive clinical data for WVE-007, WVE-006, and WVE-N531 programs.

Wave Life Sciences announced positive Phase 1b/2a RestorAATion-2 study data for WVE-006 in alpha-1 antitrypsin deficiency, showing durable AAT protein production and a favorable safety profile.

Wave Life Sciences Ltd. shareholders approved an increase of 8 million ordinary shares for its 2021 Equity Incentive Plan and re-elected all nine directors at the 2025 Annual General Meeting.

Wave Life Sciences Ltd. updated its corporate presentation, highlighting significant progress across its RNA medicine pipeline for obesity, AATD, DMD, and Huntington's Disease, with key clinical data and regulatory submissions anticipated.

Wave Life Sciences announced its second quarter 2025 financial results, revealing increased net losses and decreased revenue, while highlighting significant progress across its clinical pipeline for AATD, obesity, DMD, and HD.

Wave Life Sciences announced its Q1 2025 financial results and provided a business update, highlighting progress in its obesity, AATD, DMD, and HD programs.

Wave Life Sciences reports positive results from its FORWARD-53 clinical trial, showing significant functional benefits and reversal of muscle damage in boys with Duchenne muscular dystrophy (DMD) treated with WVE-N531, and plans to file a New Drug Application (NDA) in 2026.

Wave Life Sciences reports financial results for Q4 and full year 2024, highlighting progress in clinical trials and a strong cash position.

Wave Life Sciences is making significant strides in RNA therapeutics, showcasing positive clinical data across multiple programs and expanding its pipeline with new targets.

Wave Life Sciences updated its corporate presentation, showcasing advancements in its RNA medicines platform and pipeline, including clinical trial progress and strategic collaborations.

Wave Life Sciences announced positive clinical updates, including the first-ever demonstration of RNA editing in humans, and provided a business update alongside its third quarter 2024 financial results.

Wave Life Sciences announced advancements in its pipeline, including a new obesity therapeutic and novel RNA editing programs, at its virtual Research Day.

Wave Life Sciences announced positive proof-of-mechanism data from its WVE-006 trial, demonstrating the first-ever clinical achievement of RNA editing in humans for alpha-1 antitrypsin deficiency (AATD).